ライフサイエンスコーパス: creatine kinase MB

1 models and included haptoglobin, IL-10, and creatine kinase-MB.

2 n the activity of creatine phosphokinase and creatine kinase-MB.

3 measured by ECG, echocardiography and plasma creatine kinase-MB.

4 utcome information as a cutoff of 5x ULN for creatine kinase-MB.

5 43; P=0.003 and hazard ratio per doubling of creatine kinase-MB, 1.30; 95% confidence interval, 1.05-

6 ocardial infarction defined by enzymes (peak creatine kinase-MB 173+/-119 U/L) were scanned twice by

7 re defined: MMS-1 (all 3 markers) and MMS-2 (creatine kinase-MB and troponin I only).

8 No significant changes in creatine kinase-MB and troponin-I were seen.

9 Men were more likely to have elevated creatine kinase-MB and troponins, whereas women were mor

10 function, and perfusion), injury biomarkers (creatine-kinase-MB and troponin I), and histopathologic

11 Myoglobin, creatine kinase-MB, and troponin I were measured at 0, 3

12 Infarct size determined by creatine kinase-MB area under the curve was the primary

13 Infarct size by creatine kinase-MB area under the curve, the primary out

14 activity but reduced neither infarct size by creatine kinase-MB assessment nor adverse clinical outco

15 similar or lower in HBOC than HEX pigs, but creatine kinase-MB (but not creatine kinase-MB/creatine

16 of serum levels of cardiac troponin T, serum creatine kinase MB (CK-MB) levels, and electrocardiograp

17 cell count (WBC), C-reactive protein (CRP), creatine kinase MB (CK-MB), and troponin I levels were m

18 Serum creatine kinase-MB (CK-MB) and cardiac troponin T (cTnT)

19 Creatine kinase-MB (CK-MB) and cardiac troponins (cTn) a

20 Mild elevations in creatine kinase-MB (CK-MB) are common after successful p

21 cally evident complications to elevations of creatine kinase-MB (CK-MB) enzyme levels during percutan

22 The role of serum troponin T (TnT) and creatine kinase-MB (CK-MB) for the risk stratification o

23 nts with unstable angina were determined for creatine kinase-MB (CK-MB) subforms, myoglobin, total CK

24 ditis Treatment Trial and were compared with creatine kinase-MB (CK-MB) values measured in the same p

25 (TnI), B-type natriuretic peptide (BNP), and creatine kinase-MB (CK-MB), and TnI and BNP by CART.

26 e diagnostic performance of serum myoglobin, creatine-kinase-MB (CK-MB) and cardiac troponin-I (cTnI)

27 an HEX pigs, but creatine kinase-MB (but not creatine kinase-MB/creatine kinase ratio) was higher wit

28 Evidence of MI with creatine kinase-MB elevation after PCI was seen in 36% o

29 l-resistant patients had higher incidence of creatine kinase-MB elevation than the respective sensiti

30 revious 24 hours and ischemic ECG changes or creatine kinase-MB elevation were eligible for enrollmen

31 Slow flow was observed in 3% and creatine kinase-MB enzyme elevation >3x normal occurred

32 ity C-reactive protein (hs-CRP), Troponin-T, creatine kinase-MB, fibrinogen, and D-Dimer concentratio

33 Elevation of serum creatine kinase MB fraction (CK-MB) after percutaneous c

34 sed with increasing levels of periprocedural creatine kinase MB fraction elevation.

35 ons, with no deaths, myocardial infarctions (creatine kinase, MB fraction > 50 IU/liter) or emergent

36 rdial infarction were identified by elevated creatine kinase, MB fraction (CK-MB) and one of the foll

37 Serum markers such as myoglobin and creatine kinase, MB fraction (CK-MB) are effective in de

38 d the predictive properties of P-selectin to creatine kinase, MB fraction (CK-MB) for detecting acute

39 easurements of cardiac troponin I (cTnI) and creatine kinase, MB fraction (CK-MB) levels before, imme

40 n acute coronary syndrome (ACS) and negative creatine kinase, MB fraction (CK-MB) levels.

41 were triaged to a chest pain unit, cTnT and creatine kinase, MB fraction (CK-MB) were evaluated > or

42 Creatine kinase, MB fraction had a higher specificity fo

43 Creatine kinase, MB fraction values were determined usin

44 cTnI and creatine kinase-MB fraction (CK-MB) mass concentration w

45 ungstate significantly decreased circulating creatine kinase-MB fraction activity after hepatoenteric

46 Finally, circulating creatine kinase-MB fraction activity was significantly a

47 injury, manifested by increased circulating creatine kinase-MB fraction activity, was significantly

48 Cardiac biomarkers (creatine kinase-MB fraction or troponin I) were elevated

49 integrated into clinical algorithms such as creatine kinase-MB fraction or troponin testing for acut

50 e cardiac events, post-PCI peak troponin and creatine kinase-MB fraction, and a longer length of stay

51 fore presentation, and elevation in baseline creatine kinase-MB fraction.

52 dural non-Q-wave myocardial infarction (MI) (creatine kinase-MB > or =5 times normal) was notably hig

53 graft surgery [2.8% versus 3.3%]), although creatine kinase-MB >3X normal was more common with DCA (

54 similar information as a value of 5x ULN for creatine kinase-MB (hazard ratio, 4.31; 99% confidence i

55 We measured troponin T, troponin I and creatine kinase MB in 51 patients presenting with suspec

56 00 fg/ml troponin T, creatine kinase MM, and creatine kinase MB in serum.

57 Elevated serum levels of creatine kinase (MB isoenzyme), troponin I, and troponin

58 ved hemodynamics and decreased the levels of creatine kinase, MB isoenzyme of creatine kinase, blood

59 dy evaluated the incidence and predictors of creatine kinase-MB isoenzyme (CK-MB) elevation after suc

60 the impact of aggressive stent expansion on creatine kinase-MB isoenzyme (CK-MB) release and clinica

61 Creatine kinase-MB isoenzyme elevation occurred in 25.6%

62 PMI was defined as creatine kinase-MB isoenzyme level > or = 10x upper limi

63 re hemodynamic deterioration, preangiography creatine kinase-MB isoenzyme rise >2 x normal, and time

64 Plasma creatine kinase (MB isoform), indicating myocardial inju

65 Creatine kinase MB isoform elevation after revasculariza

66 eroxidase levels, in contrast to troponin T, creatine kinase MB isoform, and C-reactive protein level

67 study was to assess the long-term impact of creatine kinase-MB isoform (CK-MB) elevation after percu

68 Creatine kinase-MB isoform elevation only above 10 x ULN

69 (cardiac troponin I level > or =0.7 ng/mL or creatine kinase-MB level > or =5.0 ng/mL and/or diagnost

70 rdial infarction was classified according to creatine kinase-MB level as type 1 (>1 but <3 times norm

71 images provided equal performance, and peak creatine kinase-MB levels correlated with MRI infarct si

72 Creatine kinase-MB levels were measured after the proced

73 combined with select clinical variables and creatine kinase-MB levels, enhances the noninvasive pred

74 Postprocedural cTnT and creatine kinase-MB mass levels (ULN, 6.7 ng/mL in men an

75 Creatine kinase MB, MB isoforms, and troponins I and T w

76 tive model containing clinical variables and creatine kinase-MB measures, its contribution remained s

77 There was no increase in creatine kinase-MB or troponin associated with the adven

78 Fewer women had elevated creatine kinase-MB or troponins, whereas more had elevat

79 thickening score, was not predicted by peak creatine kinase-MB (P=0.66) or by total infarct size, as

80 Troponin-T and creatine kinase-MB peaked at day 1 after procedure (both

81 re was a 40% reduction in myocardial injury (creatine kinase-MB release, P=0.05) in patients who rece

82 Myoglobin, creatine kinase-MB subfraction (CK-MB) and troponin I (c

83 and serial myocardial marker measurements of creatine kinase-MB, total creatine kinase activity, and

84 Maximum creatine kinase and creatine kinase-MB values declined (5.2% and 7.6%; P<0.0

85 asures with models that include clinical and creatine kinase-MB variables.

86 In 3 patients, the creatine kinase-MB was not measured during the hospital